Harrow (NASDAQ:HROW) Coverage Initiated at Cantor Fitzgerald

Equities research analysts at Cantor Fitzgerald began coverage on shares of Harrow (NASDAQ:HROWGet Free Report) in a research report issued to clients and investors on Friday, MarketBeat Ratings reports. The firm set an “overweight” rating and a $76.00 price target on the stock. Cantor Fitzgerald’s price target would indicate a potential upside of 117.58% from the company’s current price.

A number of other equities analysts have also recently commented on the company. B. Riley lowered their target price on Harrow from $69.00 to $65.00 and set a “buy” rating for the company in a report on Tuesday, April 1st. William Blair began coverage on shares of Harrow in a report on Tuesday, June 10th. They issued an “outperform” rating for the company. BTIG Research initiated coverage on shares of Harrow in a report on Thursday, June 12th. They set a “buy” rating and a $62.00 target price on the stock. Finally, HC Wainwright raised their price target on shares of Harrow from $57.00 to $60.00 and gave the company a “buy” rating in a research report on Monday, May 12th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $63.83.

Get Our Latest Report on Harrow

Harrow Trading Up 11.3%

Shares of HROW stock opened at $34.93 on Friday. Harrow has a 1-year low of $20.85 and a 1-year high of $59.23. The firm has a market cap of $1.28 billion, a PE ratio of -62.37 and a beta of 0.41. The company has a 50-day moving average of $29.03 and a two-hundred day moving average of $28.79. The company has a debt-to-equity ratio of 2.01, a current ratio of 0.91 and a quick ratio of 0.85.

Harrow (NASDAQ:HROWGet Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.38) earnings per share for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.40). The company had revenue of $47.83 million for the quarter, compared to analysts’ expectations of $57.00 million. Harrow had a negative return on equity of 25.01% and a negative net margin of 10.19%. On average, analysts predict that Harrow will post -0.53 EPS for the current year.

Institutional Investors Weigh In On Harrow

Hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. increased its holdings in Harrow by 0.3% in the fourth quarter. Vanguard Group Inc. now owns 1,872,100 shares of the company’s stock valued at $62,809,000 after buying an additional 5,225 shares during the last quarter. Braidwell LP increased its holdings in shares of Harrow by 5.5% in the 1st quarter. Braidwell LP now owns 956,839 shares of the company’s stock valued at $25,452,000 after acquiring an additional 49,800 shares during the last quarter. D. E. Shaw & Co. Inc. raised its position in shares of Harrow by 6.7% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 664,714 shares of the company’s stock worth $22,301,000 after acquiring an additional 41,896 shares in the last quarter. Voya Investment Management LLC raised its position in shares of Harrow by 4,035.5% during the 1st quarter. Voya Investment Management LLC now owns 381,461 shares of the company’s stock worth $10,147,000 after acquiring an additional 372,237 shares in the last quarter. Finally, Royce & Associates LP lifted its stake in Harrow by 12.0% during the first quarter. Royce & Associates LP now owns 327,096 shares of the company’s stock worth $8,701,000 after purchasing an additional 35,006 shares during the last quarter. 72.76% of the stock is currently owned by institutional investors and hedge funds.

About Harrow

(Get Free Report)

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.

See Also

Analyst Recommendations for Harrow (NASDAQ:HROW)

Receive News & Ratings for Harrow Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harrow and related companies with MarketBeat.com's FREE daily email newsletter.